Advertisement
American Journal of Kidney Diseases

Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation

      Background

      Although warfarin is indicated to prevent ischemic strokes in most patients with atrial fibrillation (AF), evidence supporting its use in hemodialysis patients is limited. Our aim was to examine outcomes after warfarin therapy initiation, relative to no warfarin use, following incident AF in a large cohort of hemodialysis patients who had comprehensive prescription drug coverage through Medicare Part D.

      Study Design

      Retrospective observational cohort study.

      Setting & Participants

      Patients in the US Renal Data System undergoing maintenance hemodialysis who had AF newly diagnosed in 2007 to 2011, with Medicare Part D coverage, who had no recorded history of warfarin use.

      Predictor

      Warfarin therapy initiation, identified by a filled prescription within 30 days of the AF event.

      Outcomes

      Death, ischemic stroke, hemorrhagic stroke, severe gastrointestinal bleeding, and composite outcomes.

      Measurements

      HRs estimated by applying Cox regression to an inverse probability of treatment and censoring-weighted cohort.

      Results

      Of 12,284 patients with newly diagnosed AF, 1,838 (15%) initiated warfarin therapy within 30 days; however, ∼70% discontinued its use within 1 year. In intention-to-treat analyses, warfarin use was marginally associated with a reduced risk of ischemic stroke (HR, 0.68; 95% CI, 0.47-0.99), but not with the other outcomes. In as-treated analyses, warfarin use was associated with reduced mortality (HR, 0.84; 95% CI, 0.73-0.97).

      Limitations

      Short observation period, limited number of nonfatal events, limited generalizability of results to more affluent patients.

      Conclusions

      In hemodialysis patients with incident AF, warfarin use was marginally associated with reduced risk of ischemic stroke, and there was a signal toward reduced mortality in as-treated analyses. These results support clinical equipoise regarding the use of warfarin in hemodialysis patients and underscore the need for randomized trials to fill this evidence gap.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Go A.S.
        • Mozaffarian D.
        • Roger V.L.
        • et al.
        Heart disease and stroke statistics—2014 update: a report from the American Heart Association.
        Circulation. 2014; 129: e28-e292
        • Alonso A.
        • Lopez F.L.
        • Matsushita K.
        • et al.
        Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study.
        Circulation. 2011; 123: 2946-2953
        • Goldstein B.A.
        • Arce C.M.
        • Hlatky M.A.
        • Turakhia M.
        • Setoguchi S.
        • Winkelmayer W.C.
        Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States.
        Circulation. 2012; 126: 2293-2301
        • Piccini J.P.
        • Hammill B.G.
        • Sinner M.F.
        • et al.
        Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007.
        Circulation Cardiovasc Qual Outcomes. 2012; 5: 85-93
        • Fuster V.
        • Ryden L.E.
        • Cannom D.S.
        • et al.
        ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
        Circulation. 2006; 114: e257-e354
        • Chan K.E.
        • Lazarus J.M.
        • Thadhani R.
        • Hakim R.M.
        Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.
        J Am Soc Nephrol. 2009; 20: 2223-2233
        • Wizemann V.
        • Tong L.
        • Satayathum S.
        • et al.
        Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy.
        Kidney Int. 2010; 77: 1098-1106
        • Winkelmayer W.C.
        • Liu J.
        • Setoguchi S.
        • Choudhry N.K.
        Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.
        Clin J Am Soc Nephrol. 2011; 6: 2662-2668
        • Shah M.
        • Avgil Tsadok M.
        • Jackevicius C.A.
        • et al.
        Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.
        Circulation. 2014; 129: 1196-1203
        • Herzog C.A.
        • Asinger R.W.
        • Berger A.K.
        • et al.
        Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).
        Kidney Int. 2011; 80: 572-586
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2014; 64: e1-e76
        • Chang T.I.
        • Shilane D.
        • Kazi D.S.
        • Montez-Rath M.E.
        • Hlatky M.A.
        • Winkelmayer W.C.
        Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD.
        J Am Soc Nephrol. 2012; 23: 2042-2049
        • Yang J.Y.
        • Lee T.C.
        • Montez-Rath M.E.
        • et al.
        Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients.
        J Am Soc Nephrol. 2012; 23: 495-506
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • de Vos C.B.
        • Crijns H.J.
        • Lip G.Y.
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • Go A.S.
        • Hylek E.M.
        • Chang Y.
        • et al.
        Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?.
        JAMA. 2003; 290: 2685-2692
        • Austin P.C.
        Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.
        Stat Med. 2009; 28: 3083-3107
        • Robins J.M.
        • Hernan M.A.
        • Brumback B.
        Marginal structural models and causal inference in epidemiology.
        Epidemiology. 2000; 11: 550-560
        • Cole S.R.
        • Hernan M.A.
        Constructing inverse probability weights for marginal structural models.
        Am J Epidemiol. 2008; 168: 656-664
        • Harder V.S.
        • Stuart E.A.
        • Anthony J.C.
        Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research.
        Psychol Methods. 2010; 15: 234-249
      1. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. 2003. http://ideas.repec.org/c/boc/bocode/s432001.html. Accessed January 10, 2014.

        • Normand S.T.
        • Landrum M.B.
        • Guadagnoli E.
        • et al.
        Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores.
        J Clin Epidemiol. 2001; 54: 387-398
        • Hart R.G.
        • Benavente O.
        • McBride R.
        • Pearce L.A.
        Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
        Ann Intern Med. 1999; 131: 492-501
        • Shen J.I.
        • Turakhia M.P.
        • Winkelmayer W.C.
        Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?.
        Curr Opin Nephrol Hypertens. 2012; 21: 600-606
        • Nimmo C.
        • Wright M.
        • Goldsmith D.
        Management of atrial fibrillation in chronic kidney disease: double trouble.
        Am Heart J. 2013; 166: 230-239
        • Clase C.M.
        • Holden R.M.
        • Sood M.M.
        • et al.
        Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation?.
        Nephrol Dial Transplant. 2012; 27: 3719-3724
        • Seliger S.L.
        • Gillen D.L.
        • Longstreth Jr., W.T.
        • Kestenbaum B.
        • Stehman-Breen C.O.
        Elevated risk of stroke among patients with end-stage renal disease.
        Kidney Int. 2003; 64: 603-609
        • Juma S.
        • Thomson B.K.
        • Lok C.E.
        • Clase C.M.
        • Blake P.G.
        • Moist L.
        Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty.
        BMC Nephrol. 2013; 14: 174
        • Winkelmayer W.C.
        • Liu J.
        • Patrick A.R.
        • Setoguchi S.
        • Choudhry N.K.
        Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis.
        J Nephrol. 2012; 25: 341-353
        • Olesen J.B.
        • Lip G.Y.
        • Kamper A.L.
        • et al.
        Stroke and bleeding in atrial fibrillation with chronic kidney disease.
        N Engl J Med. 2012; 367: 625-635
        • Carrero J.J.
        • Evans M.
        • Szummer K.
        • et al.
        Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.
        JAMA. 2014; 311: 919-928
        • Holden R.M.
        • Harman G.J.
        • Wang M.
        • Holland D.
        • Day A.G.
        Major bleeding in hemodialysis patients.
        Clin J Am Soc Nephrol. 2008; 3: 105-110
        • Chan K.E.
        • Lazarus J.M.
        • Thadhani R.
        • Hakim R.M.
        Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients.
        J Am Soc Nephrol. 2009; 20: 872-881
        • Chang T.I.
        • Winkelmayer W.C.
        Comparative effectiveness research: what is it and why do we need it in nephrology?.
        Nephrol Dial Transplant. 2012; 27: 2156-2161
        • Ray W.A.
        Evaluating medication effects outside of clinical trials: new-user designs.
        Am J Epidemiol. 2003; 158: 915-920
      2. US Census Bureau GD. Census Bureau Regions and Divisions with State FIPS Codes. http://www.census.gov/geo/www/reg_div.txt. Accessed January 5, 2012.

        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation.
        Chest. 2010; 137: 263-272